NUVB Stock Analysis: Buy, Sell, or Hold?
NUVB - Nuvation Bio Inc.
$6.93
0.10 (1.46%)
▲
5d:
+11.41%
30d:
+6.78%
90d:
+44.68%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Get Alerted When NUVB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: NUVB shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: NUVB shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: NUVB is currently trading at $6.93, which is considered extended relative to its 30-day fair value range of $6.03 to $6.77. From a valuation perspective, the stock is trading at a discount (Forward PE: -462.0) compared to its historical average (86.0). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, NUVB is in a strong uptrend. Immediate support is located at $5.88, while resistance sits at $7.58.
Market Sentiment: NUVB scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.10 (+89.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, NUVB is in a strong uptrend. Immediate support is located at $5.88, while resistance sits at $7.58.
Market Sentiment: NUVB scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $13.10 (+89.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$6.03 -
$6.77
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
33.3%
Protect Your Profits
Holding NUVB? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (10/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 89.0% below Wall St target ($13.10)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 40/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$6.03 -
$6.77
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.88
Resistance Level
$7.58
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-462.00
Wall Street Target
$13.10
(+89.0%)
Revenue Growth (YoY)
555.6%
Profit Margin
-88.2%
PE vs Historical
-462.0 vs 86.0
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 12:06 AM ET
Data refreshes hourly during market hours. Next update: 1:06 AM
Data refreshes hourly during market hours. Next update: 1:06 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NUVB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Dongfang Liu
SELL
50000 shares
2026-04-17
Kerry Wentworth
SELL
36750 shares
2026-04-17
Kerry Wentworth
SELL
200000 shares
2026-04-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1173 | 43 HOLD |
|
LEGN
Legend Biotech Corp |
STRONG BUY
22 analysts |
$49 | 39 SELL |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 26 SELL |
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$840 | 34 SELL |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
Advanced NUVB Option Strategies
Professional options setups generated by AI based on today's NUVB price and gamma walls.